Abstract Preeclampsia is characterized by maternal systemic anti-angiogenic and pro-inflammatory states. Syndecan-1 is a cell surface proteoglycan expressed by the syncytiotrophoblast, which plays an important role in angiogenesis and resolution of inflammation. Our aim was to examine placental syndecan-1 expression in preeclampsia with or without hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome. Placentas were obtained from women in the following groups: (1) late-onset preeclampsia (n=8); (2) early-onset preeclampsia without (n=7) and (3) with HELLP syndrome (n=8); (4) preterm controls (n=5); and (5) term controls (n=9). Tissue microarrays (TMAs) were constructed from paraffinembedded placentas. TMA slides were immunostained for syndecan-1 and evaluated using microscopy, virtual microscopy, and semi-automated image analysis. Maternal sera from patients with preeclampsia (n=49) and controls (n=32) were immunoassayed for syndecan-1. BeWo cells were treated with Forskolin or Latrunculin B or kept in ischemic conditions. SDC1 expression and syndecan-1 production were investigated with qRT-PCR, confocal microscopy, and immunoassays. Syndecan-1 was localized to the syncytiotrophoblast apical membrane in normal placentas. Syndecan-1 immunoscores were higher in late-onset preeclampsia (p=0.0001) and early-onset preeclampsia with or without HELLP syndrome (p=0.02 for both) than in controls. Maternal serum syndecan-1 concentration was lower in preeclampsia (median, 673 ng/ml; interquartile range, 459-1,161 ng/ml) than in controls (1,158 ng/ml; 622-1,480 ng/ml). SDC1 expression and syndecan-1 immunostainings in BeWo cells and syndecan-1 concentrations in supernatants increased during cell differentiation. Disruption of the actin cytoskeleton with Latrunculin B decreased syndecan-1 release, while ischemic conditions increased it. Syncytiotrophoblastic syndecan-1 expression depends on the differentiation of villous trophoblasts, and trophoblastic syndecan-1 release is decreased in preeclampsia and HELLP syndrome. This phenomenon may be related to the disturbed syncytiotrophoblastic cortical actin cytoskeleton and associated with maternal anti-angiogenic and proinflammatory states in these syndromes.
SDC1 expression and syndecan-1 production were investigated with qRT-PCR, confocal microscopy, and immunoassays. Syndecan-1 was localized to the syncytiotrophoblast apical membrane in normal placentas. Syndecan-1 immunoscores were higher in late-onset preeclampsia (p=0.0001) and early-onset preeclampsia with or without HELLP syndrome (p=0.02 for both) than in controls. Maternal serum syndecan-1 concentration was lower in preeclampsia (median, 673 ng/ml; interquartile range, 459-1,161 ng/ml) than in controls (1,158 ng/ml; 622-1,480 ng/ml). SDC1 expression and syndecan-1 immunostainings in BeWo cells and syndecan-1 concentrations in supernatants increased during cell differentiation. Disruption of the actin cytoskeleton with Latrunculin B decreased syndecan-1 release, while ischemic conditions increased it. Syncytiotrophoblastic syndecan-1 expression depends on the differentiation of villous trophoblasts, and trophoblastic syndecan-1 release is decreased in preeclampsia and HELLP syndrome. This phenomenon may be related to
Introduction
Preeclampsia is one of the "great obstetrical syndromes" [1] that affects 3-5 % of human pregnancies and is a major cause of maternal, perinatal, and neonatal mortality and morbidity worldwide [2] . Preeclampsia is diagnosed by the presence of proteinuria and new-onset hypertension after 20 weeks of gestation and may cause maternal multiorgan damage affecting the kidneys, liver, and central nervous system [2, 3] . Preeclampsia has two major subtypes: early-onset preeclampsia (which develops before 34-35 weeks of gestation) and lateonset preeclampsia (which develops later during gestation) [2] [3] [4] [5] . Late-onset preeclampsia represents the majority of cases, is more frequent among healthy nulliparous women, is often mild, and primarily results in maternal consequences. Earlyonset preeclampsia is primarily a disease of multiparous women, is more severe, and is often associated with life-threatening hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome [2] [3] [4] [5] . This syndrome is a consequence of microangiopathic hemolytic anemia, hepatocellular injury, and consumptive thrombocytopenia, leading to characteristic changes in laboratory findings associated with hemolysis, abnormal liver function, and thrombocytopenia [3, 6, 7] . Originally, HELLP syndrome was thought to be a severe variant of preeclampsia, but subsequent studies suggested that it is a separate clinical entity [3, 6] . Indeed, one fifth of HELLP syndrome patients do not have hypertension and/or proteinuria [3, 6, 7] .
Although the exact pathophysiologies of preeclampsia and HELLP syndrome are still incompletely understood, it is evident that the placenta plays an important role in their pathogeneses, as their only current specific therapy is the delivery of the fetus and placenta. However, placental involvement in the pathogenesis of preeclampsia varies in extent as there is a high frequency of placental histopathological lesions observed in cases of early-onset preeclampsia and HELLP syndrome, while placental histopathological abnormalities are less frequent in cases of late-onset preeclampsia [2, 3, [8] [9] [10] [11] . The extent of placental transcriptomics changes in late-onset and early-onset preeclampsia is also different when compared to gestational age-matched controls, but similar between earlyonset preeclampsia and HELLP syndrome [12] [13] [14] . Irrespective of the observed differences, various subforms of preeclampsia and HELLP syndrome are associated with an increased release of anti-angiogenic molecules and trophoblastic debris from the chorionic villi, which lead to generalized maternal endothelial cell dysfunction and increased systemic inflammation, a common terminal pathway in these syndromes [2] [3] [4] [15] [16] [17] [18] [19] [20] [21] [22] [23] .
Syndecans are transmembrane proteoglycans that regulate various physiological processes including angiogenesis and inflammation [24] [25] [26] . The syndecan family consists of four members that evolved by gene duplication [24, 25] . Syndecans contain heparan sulfate and chondroitin sulfate chains that allow for specific interactions with a variety of ligands, including vascular endothelial growth factor, transforming growth factor beta, and fibronectin, which all have important functions in the placenta [27] . Syndecan-1 is a cell surface heparan sulfate proteoglycan highly expressed in the syncytiotrophoblast layer of the chorionic villi in the human placenta [28] [29] [30] [31] . It is involved in the regulation of cell behavior through its abilities to bind growth factors and to interact with components of the extracellular matrix, playing an important role in cell-cell and cell-extracellular matrix interactions, and in cell signaling [24] [25] [26] .
The exact placental functions of syndecan-1 and its possible involvement in the development of placental pathologies are still obscure [29] . Two recent publications noted that preeclampsia is accompanied by the decreased syncytiotrophoblastic expression of syndecan-1 [28, 30] , while another study described increased syncytiotrophoblastic expression of this proteoglycan in cases of preeclampsia [31] . Thus far, no data have been published on the placental behavior of this proteoglycan for patients with HELLP syndrome. The aims of this study were: (1) to examine the changes in the expression of syndecan-1 in the chorionic villi of the placenta, particularly in the syncytiotrophoblast, in various subforms of preeclampsia and HELLP syndrome; and (2) to model villous trophoblastic expression of syndecan-1 under normal conditions and in preeclampsia in trophoblast-like BeWo cells.
Materials and methods
Patient groups, clinical samples, and definitions The Health Science Board (Budapest, Hungary) and the Institutional Review Boards of Wayne State University (Detroit, MI, USA) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), U.S. Department of Health and Human Services (DHHS) (Bethesda, MD, and Detroit, MI, USA) approved the collection and use of materials for research purposes. Informed consent was obtained from all women prior to sample collection. Specimens and data were collected and stored anonymously.
Placental specimens were collected at the First Department of Obstetrics and Gynecology, Semmelweis University (Budapest, Hungary). Women were enrolled in the following groups: (1) late-onset preeclampsia (n=8); (2) early-onset preeclampsia (n=7); (3) early-onset preeclampsia with HELLP syndrome (n=8); (4) preterm controls (n=5); and (5) term controls (n=9) ( Table 1) . Maternal blood specimens (n=81) were selected from the Bank of Biological Materials of the Perinatology Research Branch, NICHD/NIH/DHHS (Detroit, Michigan). Patients were included in the following groups: (1) preterm and term preeclampsia (n=49); and (2) gestational age-matched controls (n=32) ( Table 2) . Patients with fetal congenital anomalies and multiple gestations at each site were excluded from the study. Blood specimens were collected within a week before delivery, and sera were collected by centrifuging blood at 1,300×g for 10 min at 4°C, and then stored at −70°C.
Preeclampsia was defined as new-onset hypertension (systolic or diastolic blood pressure ≥140 or ≥90 mmHg, respectively, measured at two time points, 4 h to 1 week apart) developing after 20 weeks of gestation along with proteinuria (≥300 mg during a 24-h urine collection or two random urine specimens obtained 4 h to 1 week apart containing ≥1+ by dipstick or one dipstick of ≥2+ protein) [2, 32, 33] . HELLP syndrome was defined by the presence of hemolysis (serum LDH >600 IU/l; bilirubin >1.2 mg/dl; presence of schistocytes in peripheral blood), elevated liver enzymes (serum ALT and/or AST >70 IU/l), and thrombocytopenia (platelet count <100,000/mm 3 ), developing after 20 weeks of gestation [34] . The term "small-for-gestational-age" (SGA) was defined as neonatal birth weight below the 10th percentile for gestational age according to the national birth weight distribution curves [35, 36] . No medical or obstetrical complications were detected in term controls who delivered a neonate with a birth weight appropriate for gestational age. Preterm controls had preterm deliveries with no clinical or histological signs of chorioamnionitis and delivered a neonate with a birth weight appropriate for gestational age.
Placental specimens and histopathological evaluations Placentas were obtained following Caesarean deliveries. For microarray studies, villous tissue samples were excised from central cotyledons, and microarray analysis was performed as previously described [13] . Placentas were examined according to a standard histopathological protocol that describes the topography and size of macroscopic lesions [13, 37] and then fixed in formalin. For tissue microarray, five representative histological Staining intensities (+1, +2, or +3) of all scored villi in a given core were averaged, and this score was used as the representative data for that core. In addition, visual evaluation of immunostaining was also performed by three examiners who were blinded to the clinical information and used an Axioskop 2 plus light microscope (Carl Zeiss MicroImaging GmbH, Gottingen, Germany). Subsequently, tissue microarray (TMA) slides were digitally scanned with a high-resolution scanner (Pannoramic Scan, 3DHISTECH Ltd.), and image data were deposited into a virtual laboratory (www.pathonet.org) and used for virtual microscopic evaluation with the Pannoramic Viewer 1.15 (3DHISTECH Ltd.) [37] . Virtual slides were independently evaluated by the same examiners. In both cases, immunostaining of the syncytiotrophoblast brush border membrane was semiquantitatively scored using an immunoreactive score modified from that previously described [37] . Briefly, at least 25 terminal or intermediate villi with a diameter of 20-150 μm were evaluated in each core. Staining intensities (0, +1, +2, or +3) of the villi in a given core were averaged, and this score was used as the representative data for that core.
BeWo cell cultures BeWo cells (American Type Culture
Collection, Manassas, VA, USA) were cultured with F12 medium (Invitrogen, Life Technologies Corporation, Carlsbad, CA, USA) supplemented with 10 % fetal bovine serum and 1 % penicillin/streptomycin. Cells were either plated on six-well plates (0.5×10 6 /plate) or on Nunc® LabTek II® chambered coverglass slides (0.3×10 6 /chamber) (Thermo Scientific, Wilmington, DE, USA) and were used for various experiments: (1) to test the effect of trophoblast Cell culture supernatants were collected from six-well plates on each day and used for immunoassays. Total RNAwas isolated from cells in six-well plates on each day with the RNeasy® Mini Kit and RNase-Free DNase Set (Qiagen, Valencia, CA, USA). The RNA concentrations were measured with the NanoDrop1000 Spectrophotometer (Thermo Scientific). Total RNA (500 ng) was reverse transcribed with the SuperScript® III First-Strand Synthesis System (Invitrogen). TaqMan® Assays (Applied Biosystems, Life Technologies Corporation) for SDC1 (Hs00896423_m1) and RPLP0 (large ribosomal protein; Endogenous Control; 4326314E) were used for gene expression profiling on an ABI 7500 Fast Real-Time PCR System (Applied Biosystems). Cells in chambered coverglass slides were fixed with 4 % paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA, USA), blocked with Protein Block (Dako North America, Inc., Carpinteria, CA, USA) and stained overnight at 4°C with a mouse monoclonal anti-human syndecan-1 antibody (clone MI15; 5 μg/ml; Novus Biologicals, LLC, Littleton, CO, USA). After repeated washes, Alexa Fluor® 488 goat anti-mouse IgG (Invitrogen) was added at 1:1,000 dilution in PBS with 10 % normal Goat Serum (MP Biomedicals, LLC, Santa Ana, CA, USA). Cells were mounted with ProLong Gold® antifade reagent and 4′,6-diamidino-2-phenylindole (DAPI; Invitrogen) and imaged by confocal microscopy using a Zeiss LSM 780 spectral confocal system (Carl Zeiss Microscopy, LLC, Thornwood, NY, USA).
Syndecan-1 immunoassays Maternal serum and cell culture supernatant syndecan-1 concentrations were measured with a human syndecan-1 ELISA Kit (Cell Sciences, Canton, MA, USA), according to the manufacturer's instructions. The sensitivity of the assay was <2.56 ng/ml, and the coefficients of intra-assay variation and inter-assay variation were 7.6 and 6.8 %, respectively, according to the manufacturer.
Statistical analysis Demographic data were analyzed using SPSS version 12.0 (SPSS Inc., Chicago, IL, USA). Comparisons among the groups were performed using Chisquare and Fisher's exact tests for proportions, Kruskal-Wallis and Mann-Whitney tests for non-normally distributed continuous variables, and the t test for normally distributed continuous variables. Pearson coefficients and associated p values were calculated for the correlation between maternal serum syndecan-1 concentrations and clinical/demographic parameters using R (www.r-project.org). A linear model was used to reveal group differences in maternal serum syndecan-1 concentrations after adjusting for gestational age and birth weight. The level of significance was set to 5 %.
Results
Demographic and clinical data Demographic and clinical characteristics of the two study populations are displayed in Tables 1 and 2 . In the placental study (Table 1) , peak systolic and diastolic blood pressures were significantly higher in all patient, but not control, groups. Proteinuria was detected in all cases except those in the control groups. Although term and preterm controls were matched to cases within 2 weeks of gestational age, the median gestational age at delivery of term controls was slightly higher than that of cases with late-onset preeclampsia. In the maternal serum study (Table 2) , peak systolic and diastolic blood pressures were higher in women with preeclampsia compared to the controls. Proteinuria was present in all cases, and HELLP syndrome developed in 20% of the cases with preeclampsia. Primiparity was more frequent and birth weight was lower in patients with preeclampsia.
Syndecan-1 expression is dependent on villous trophoblast differentiation In term control placentas, syndecan-1 immunostaining was confined to the syncytiotrophoblast apical membrane, displaying a linear granular structure. A moderate amount of these syndecan-1 immunopositive granules was also detected in the syncytiotrophoblast cytoplasm. No syndecan-1 immunostaining was detected in the cytotrophoblast or in other cell types of the chorionic villi (Fig. 1a) . These findings suggest that syndecan-1 expression is dependent on the differentiation of villous trophoblasts, which we aimed to model in vitro using BeWo trophoblast-like cells. Forskolin-treated BeWo cells expressed an increasing amount of SDC1 during morphological and biochemical differentiation (day 1, no change; day 2, 3.2-fold increase, p=8.3×10 ) (Fig. 1b) . Furthermore, differentiating BeWo cells released significantly higher amounts of syndecan-1 into the cell culture medium on day 2 (4.3±0.5 ng/ml, p=0.028) and day 3 (15.2± 2.0 ng/ml, p=0.008) than on day 1 (under the detection limit of 2.56 ng/ml) (Fig. 1c) . When compared to non-treated BeWo cells, Forskolin-treated BeWo cells, especially multinucleated fused cells, had strong cell membrane syndecan-1 immunostaining on day 3 of the cultures. In accordance with placental findings, we also detected a punctuate pattern of cell membrane and cytoplasmic syndecan-1 immunostaining in these BeWo cells (Fig. 1d) .
Placental syndecan-1 mRNA expression is not affected by preeclampsia Since it was previously hypothesized that preeclampsia may be related to the dysregulation of the differentiation of villous trophoblasts, we reinvestigated our microarray data [13] on putative changes in SDC1 expression in preeclampsia. We did not find any significant difference in placental SDC1 expression for early-onset preeclampsia, either complicated with (1.43-fold downregulation, adjusted p=0.74) or without (1.56-fold downregulation, adjusted p=0.65) HELLP syndrome when compared to the control group (data not shown).
Placental syndecan-1 immunoreactivity is increased in preeclampsia and HELLP syndrome Next, we evaluated placental syndecan-1 expression for cases of preeclampsia with or without HELLP syndrome. As shown in Fig. 2 , the most profound alteration was observed in cases with early-onset preeclampsia where the cytoplasm of the syncytiotrophoblast gave a strong immunoreaction, and the syncytiotrophoblast apical membrane was immunonegative for this proteoglycan in several cases. Similar but less intensive syndecan-1 immunostaining of the syncytiotrophoblast cytoplasm was observed ). c Syndecan-1 release into the cell culture medium significantly increased from the second day of differentiation in Forskolin-treated BeWo cells (day 2, 4.3 ng/ml, p=0.028; day 3, 15.2 ng/ml, p=0.008). d Forskolin-treated BeWo cells had strong cell membrane syndecan-1 immunostaining on day 3 of culture compared to non-treated BeWo cells. A punctuate cell membrane and cytoplasmic syndecan-1 staining could also be detected in BeWo cells (DAPI counterstain, ×1,500 magnification) in late-onset preeclampsia specimens. In cases of early-onset preeclampsia with HELLP syndrome, the syncytiotrophoblast apical membrane showed strong linear positivity. The syncytiotrophoblast also showed signs of syndecan-1 release to the intervillous space in 29-55 % of cases in all study groups and to a somewhat larger extent in cases with early-onset preeclampsia and HELLP syndrome than in the control groups (Fig. 2) .
To objectively semiquantify placental syndecan-1 immunostaining on scanned TMA slides, we used the newly developed Pannoramic Viewer v1.15 of MembraneQuant and found that: (1) syndecan-1 immunostaining did not change with gestational age as immunoscores in preterm and term control groups were similar (2.33±0.33 versus 2.29±0.33, p=0.66); (2) syndecan-1 immunoscores were higher in cases of late-onset preeclampsia than in the term control group (2.59±0.26 versus 2.29±0.33; p=0.0001); (3) syndecan-1 immunoscores were higher in cases of early-onset HELLP syndrome than in the preterm control group (2.63±0.23 versus 2.33±0.33; p=0.02); and (4) syndecan-1 immunoscores were higher in cases of early-onset preeclampsia than in the preterm control group (2.59±0.36 versus 2.33±0.33; p=0.02) (Fig. 3) . These findings were supported by microscopic and virtual microscopic evaluations and semiquantitative TMA immunoscorings, although these latter scoring systems differed slightly ( Supplementary Figs. 1  and 2 ).
Maternal serum syndecan-1 concentrations are decreased in preeclampsia Next, we investigated how maternal serum syndecan-1 concentrations changed in preeclampsia. Our study population consisted of early-onset and late-onset preeclampsia cases and gestational age-matched controls. Seven women with early-onset preeclampsia and three with late-onset preeclampsia also had HELLP syndrome. Maternal serum syndecan-1 Fig. 2 Placental syndecan-1 immunostaining is increased in preeclampsia and HELLP syndrome. a-c Syndecan-1 immunostaining was similar in preterm controls (a GW26 +6 , b GW35 +2 ) and term controls (c GW39 +5 ), showing a linear granular pattern, mainly confined to the syncytiotrophoblast apical membrane and moderately to the syncytiotrophoblast cytoplasm. d In early-onset preeclampsia complicated with HELLP syndrome (GW27), the syncytiotrophoblast apical membrane showed strong linear positivity. e In early-onset preeclampsia (GW34 +6 ), the cytoplasm of the syncytiotrophoblast gave strong immunoreaction. Some areas in the syncytiotrophoblast showed signs of syndecan-1 release, and the apical membrane was focally immunonegative. f Similar but less intensive cytoplasmic syndecan-1 immunostaining was observed in late-onset preeclampsia (GW40 +3 ) specimens. The syncytiotrophoblast apical membrane area is shown in larger magnification in a case of a term control (g) and early-onset preeclampsia (h). Arrows show immunonegative apical membrane regions of the syncytiotrophoblast in preeclampsia. Hematoxylin counterstain, ×400 (a-f) or ×600 (g-h) magnifications concentrations positively correlated with birth weight (R 2 = 0.25, p=1.7×10 −6 ) and gestational age (R 2 =0.22, p=1× 10 −5 ) (Fig. 4a ) and negatively correlated with mean arterial pressure (R 2 = 0.08, p = 0.012) and urine protein content (R 2 = 0.06, p = 0.039). Indeed, maternal serum syndecan-1 concentration was lower in cases with preeclampsia (median, 673 ng/ml; interquartile range (IQR), 459-1,161 ng/ml) than in the control group (median, 1,158 ng/ml; IQR, 622-1,480 ng/ml) (Fig. 4b) , even after adjusting for birth weight and gestational age (p=0.03). There was no difference in maternal serum syndecan-1 concentrations among cases of preeclampsia without HELLP syndrome (median, 718 ng/ml; IQR, 460-1,168 ng/ml) and those with (median, 546 ng/ml; IQR, 413-721 ng/ml) this syndrome. Lower maternal serum syndecan-1 concentration among cases with lower birth weight was not due to the presence of SGA pregnancies, as there were no SGA neonates delivered in the control group (Table 2) , and maternal serum syndecan-1 concentration was not different in cases of preeclampsia associated with or without SGA pregnancies (AGA, 703 ng/ml; IQR, 497-1,220 ng/ml; SGA, 617 ng/ml; IQR, 411-1,035 ng/ml; p=0.2) (Fig. 4c) .
Syndecan-1 release from BeWo cells is altered by ischemia and actin cytoskeleton disruption
To model syncytiotrophoblastic syndecan-1 release or retention in preeclampsia, we placed Forskolin-treated BeWo cells in ischemic conditions for 24 h or co-treated them for 12 h with Latrunculin B, a disruptor of the actin cytoskeleton [40] . We detected no difference in SDC1 expression for the BeWo cells kept in ischemic conditions (1.14-fold change, p=0.72) or for those treated with Latrunculin B (1.07-fold change, p=0.69) compared to the controls (Fig. 5a ). However, there was an increased release of syndecan-1 from BeWo cells into the culture medium in ischemic conditions (30±1.8 ng/ml, p=0.042) and a decreased release after Latrunculin B treatment (17.4±3.3 ng/ml, p=0.050) compared to the controls (24.0±4.2 ng/ml) (Fig. 5b) . Immunofluorescence stainings for syndecan-1 and confocal imaging of Forskolin-treated control BeWo cells revealed the strongest cell membrane syndecan-1 immunostaining of multinucleated, fused cells (Fig. 5c ). BeWo cells kept in ischemic conditions had faint cell membrane staining of syndecan-1, suggesting an increased shedding of syndecan-1 from the trophoblast cell surface into the cell culture medium, similar to the increased shedding of syndecan-1 from cell surfaces in pro-inflammatory conditions [24, 26, 41] (Fig. 5d) . Latrunculin B-treated BeWo cells had no (or faint) cell membrane syndecan-1 immunoreactivity; however, there was increased granular syndecan-1 accumulation in their cytoplasm, suggesting a defect in the cytoplasmic and cell membrane transport of syndecan-1, leading to its decreased release into the cell culture medium upon the disruption of the actin cytoskeleton (Fig. 5e) .
Discussion
Principal findings of this study (1) Syndecan-1 was mainly localized to the syncytiotrophoblast apical membrane in the chorionic villi of control placentas; (2) syndecan-1 immunostaining of the syncytiotrophoblast and its apical membrane did not change with gestational age in control placentas; (3) there was increased syndecan-1 immunostaining intensity of the syncytiotrophoblast in cases of late-onset preeclampsia and early-onset preeclampsia with or without HELLP syndrome; (4) maternal serum syndecan-1 concentration positively correlated with gestational age and birth weight, and negatively correlated with blood pressure and proteinuria; (5) maternal serum syndecan-1 concentration was lower in cases of preeclampsia than in gestational age-matched controls; (6) the presence of SGA neonates did not affect maternal serum syndecan-1 concentration in pregnancies with preeclampsia; and (7) the disruption of the actin cytoskeleton led to the accumulation of cytoplasmic syndecan-1 in BeWo cells, while ischemic stress caused increased release of syndecan-1 from BeWo cells. Placental syndecan-1 expression increases during trophoblast differentiation We found syndecan-1 immunostaining of the syncytiotrophoblast and its apical membrane; however, other cells in the chorionic villi of the placenta were immunonegative for this proteoglycan. No changes were found in syndecan-1 immunostaining with increasing gestational age during the third trimester. These findings are consistent with those of Crescimanno et al. [29] and Jokimaa et al. [28, 30] who showed similar syndecan-1 immunostaining of the syncytiotrophoblast in placentas obtained during the first and )). b Median maternal serum syndecan-1 concentration was lower in preeclampsia (673 ng/ml; IQR, 459-1,161 ng/ml) than in the control group (1,158 ng/ml; IQR, 622-1,480 ng/ml). c Maternal serum syndecan-1 concentrations were not different (p=0.2) among patients with preeclampsia who had small-for-gestational-age neonates (filled circles; median, 617 ng/ml; IQR, 411-1,035 ng/ml) and those who had appropriate-for-gestational-age neonates (open circles; median, 703 ng/ml; IQR, 497-1,220 ng/ml). GW gestational week third trimesters of pregnancy, which are also consistent with previous reports describing placental syndecan-1 expression to be restricted to the syncytiotrophoblast [28] [29] [30] [31] 42] . This suggests that syndecan-1 expression is dependent on the differentiation of the villous cytotrophoblasts to form the syncytiotrophoblast. As a confirmation, we observed increasing SDC1 expression and syndecan-1 release from BeWo trophoblast-like cells during Forskolin-induced differentiation.
The remarkable structural, functional, and metabolic changes that the villous trophoblast undergoes during its morphological and biochemical differentiation, as well as fusion into the syncytiotrophoblast, are secondary to the categorical reprogramming of the villous trophoblastic transcriptional program [43, 44] . This temporal transcriptomic reprogramming involves the induction or repression of thousands of genes, leading to the gain of a multitude of functions, some of them unique to the placenta [43] . The fascinating output of this tightly regulated process is the multinucleated syncytiotrophoblast, which plays essential roles throughout pregnancy, including materno-fetal nutrients, gas and waste exchange, synthesis of placental hormones required for fetal development, and generation of an immunological barrier between the mother and her fetus [45] . Results for the high syndecan-1 expression in the syncytiotrophoblast suggest the importance of its function(s) at the maternal-fetal barrier. Since syndecan-1 expression is developmentally regulated [25] and can also be very high in various tumors [46] [47] [48] [49] , this proteoglycan may have oncodevelopmental significance.
Placental syndecan-1 immunostaining intensity is increased in preeclampsia and HELLP syndrome While examining placental syndecan-1 expression in various disease groups, we found increased syndecan-1 immunostaining intensity of the syncytiotrophoblast apical membrane in both late-onset and early-onset preeclampsia and HELLP syndrome using microscopy, semi-automated image analysis, and virtual microscopy, which have become more and more accepted in on-line evaluations and testings [50] . These findings are consistent with the results of Ogawa et al., who used a semi-quantitative immunoscoring system and showed that syndecan-1 immunostaining of the syncytiotrophoblast was increased in cases of early-onset preeclampsia when compared to the preterm controls [31] . Interestingly, two publications from Jokimaa et al. [28, 30] presented data on faint syndecan-1 immunostaining in
Normal pregnancy
Early-onset preeclampsia Fig. 6 A possible explanation on the altered trophoblastic transport and localization of syndecan-1 in preeclampsia. During normal pregnancy, syndecan-1 is transported to the apical membrane of the syncytiotrophoblast, from where it is continuously shed into the maternal circulation. In preeclampsia, the alterations in the cortical cytoskeletal actin network lead to the accumulation of syndecan-1 below the apical membrane and, ultimately, in the cytoplasm. In early-onset preeclampsia, there may be an increased shedding of syndecan-1 from the cell surface because of increased pro-inflammatory conditions, which may explain our findings on the immunonegativity of the apical membrane for syndecan-1 in several cases. Still, the net amount of syndecan-1 shed into the maternal circulation is decreased compared to normal pregnancies. Parts of the figure were adapted from Riquelme et al. [59] , © Springer placentas of patients with late-onset and early-onset preeclampsia compared to strong immunoreactivity for syndecan-1 in placentas taken from preterm and term controls.
The discrepancy between these studies may lie in critical differences in the applied methodologies. All three previous studies utilized the same mouse monoclonal IgG1 antibody (clone B-B4) that binds to a linear epitope between residues 90 to 95 of the core protein on human syndecan-1 [51] . This B-B4 antibody reacts with the same or closely related epitope on the syndecan-1 core as the MI15 antibody used in our study [52] . The important difference among the four studies is that, similar to Ogawa et al. [31] , we used antigen retrieval by heating the paraffin sections. On the other hand, there was no mention of antigen retrieval in the publications of Jokimaa et al. [28, 30] , even though it is mandatory for syndecan-1 immunostaining of paraffin sections (DakoCytomation recommendation). Thus, a possible explanation is that the lack of antigen retrieval kept the B-B4 antibody-reactive epitope(s) masked by formalin-induced cross-links on the syndecan-1 core protein, which we observed to be accumulated in the syncytiotrophoblast in preeclampsia. It has been well established by placental morphometrical studies that placental development is altered and placental morphology is abnormal in cases of early-onset preeclampsia complicated by intrauterine growth restriction (IUGR), but these parameters are not affected in late-onset preeclampsia not complicated by IUGR [53] . It was also previously shown that the placental transcriptome is quite dissimilar in cases of late-onset and early-onset preeclampsia complicated with IUGR [12] , and that the placental gene expression signature in early-onset preeclampsia and early-onset HELLP syndrome is similar [13] . Many other characteristics and parameters observed in different subforms of preeclampsia, including the differences we found in the frequency of placental lesions consistent with maternal underperfusion [10, 13, 37] , also underline the heterogeneity of this syndrome [3] [4] [5] . In this regard, it is noteworthy that we found a general increase in syncytiotrophoblastic syndecan-1 immunostaining in various subforms of preeclampsia and HELLP syndrome, suggesting that the dysregulation of this proteoglycan in the syncytiotrophoblast may be part of the common terminal pathway of these syndromes. Nevertheless, some heterogeneity was also observed in the syncytiotrophoblastic staining pattern of this proteoglycan as were remarkable changes in its cellular distribution in preeclampsia and HELLP syndrome. There were cases with very intense immunostaining in or below the apical membrane region, especially for cases with early-onset HELLP syndrome. There were placentas for which strong cytoplasmic immunostaining was also revealed, suggesting the retention of this proteoglycan in the cytoplasm. However, in some cases, the apical membrane was completely immunonegative for syndecan-1, especially in early-onset preeclampsia, suggesting the decreased transport of syndecan-1 to the cell surface and its increased shedding from that in these cases. Indeed, syncytiotrophoblastic syndecan-1 release into the intervillous space in 29-55 % of the cases in all study groups was observed.
Maternal serum syndecan-1 concentrations are decreased in preeclampsia In accordance with this latter observation, we detected a large amount of syndecan-1 in the maternal sera between 24 and 40 weeks of gestation. Our observations supported the findings of a previous study [54] in that maternal serum syndecan-1 concentrations continuously rise during pregnancy, and these can be more than 100-fold higher than in nonpregnant women [54] . Since syndecan-1 immunostaining of the syncytiotrophoblast does not change with gestational age [28] [29] [30] , and birth weight was positively associated with maternal serum syndecan-1 concentration in this study, we propose that maternal serum syndecan-1 concentration increases with advancing gestational age due to the increase in trophoblast cell volumes and surface areas as shown by stereological methods [55] . This is the first study to evaluate maternal serum syndecan-1 concentration in preeclampsia. We found that syndecan-1 concentration was decreased in women with preeclampsia (both early and late onset) compared to gestational agematched controls at the time of the onset of clinical symptoms, in spite of the stronger placental syndecan-1 immunostaining detected in these syndromes. Since our microarray data [13] showed no change in SDC1 expression in early-onset preeclampsia or early-onset HELLP syndrome, the increased placental syndecan-1 content and the decreased maternal serum syndecan-1 concentrations suggest that there is an alteration in the syncytiotrophoblastic transport of syndecan-1 in these syndromes.
Disrupted actin cytoskeleton may inhibit syncytiotrophoblastic syndecan-1 transport It has previously been shown that syndecan-1 co-localizes with actin filaments and that cellular syndecan-1 transport is dependent on the intactness of the actin cytoskeleton [24, 25, 56] . In this context, one study revealed that the expression of a set of genes involved in the regulation of the actin cytoskeleton is characteristically down-regulated in the placenta in cases of preeclampsia [57] . Another study showed that actin and ezrin, proteins important to the structural integrity of the brush border membrane, have decreased expression in the villous cytotrophoblast in preeclampsia [58] . It was also shown that the network of cytoskeletal proteins in the apical syncytiotrophoblast membrane is significantly altered in preeclampsia [59] , and this may have a significant impact on the deformation of the syncytiotrophoblast brush border membrane in preeclampsia, as observed during an electron microscopic study [60] . Our findings on the increased retention of syndecan-1 in BeWo cells upon the disruption of the actin cytoskeleton with Latrunculin B support the hypothesis that alterations of the cortical cytoskeletal actin network in the syncytiotrophoblast in preeclampsia and HELLP syndrome will lead to the accumulation of syndecan-1 below the apical membrane and, ultimately in the cytoplasm, also leading to decreased syndecan-1 maternal serum concentration (Fig. 6) .
Another relevant finding from previous studies has shown that the integrity of lipid rafts is essential for the clustering and biological activity of syndecan-1 on cell surfaces [61, 62] . We found a granular staining pattern of syndecan-1 in the syncytiotrophoblast of the control placentas, which may be the consequence of the localization of syndecan-1 in distinct lipid raft domains of the apical brush border membrane of the syncytiotrophoblast. Interestingly, studies by Riquelme et al. found that two different lipid raft structures are distinctly associated with the classical "microvillous membrane" (MVM) and the "light microvillous membrane" (LMVM) on the syncytiotrophoblast brush border surface [63] , and that there is only one type of lipid raft in the MVM and LMVM membranes in preeclampsia, suggesting considerable differences in lipid raft structures of the syncytiotrophoblast for this syndrome [59] . Our observation on the change from a granular to a more linear membrane staining pattern of syndecan-1 in disease samples suggests that this phenomenon may be related to the altered lipid raft structures. Collectively, these results suggest that changes of the actin cytoskeleton and lipid raft structures may play a role in the altered cellular transport and localization of syndecan-1 for the syncytiotrophoblast in preeclampsia in a different manner as in the case of galectin-13 [40] .
Possible consequences of altered syndecan-1 release from the trophoblast Syndecan-1 is a transmembrane proteoglycan with heparan sulfate chains attached to its extracellular domain and has a wide variety of functions on epithelial surfaces through the binding and regulation of heparan sulfate and heparan-binding molecules [24-26, 41, 64, 65] . The physiological and pathophysiological processes that involve syndecan-1 include host defense against pathogens, leukocyte recruitment, resolution of inflammation, extracellular matrix remodeling, angiogenesis, cell signaling, proliferation and apoptosis, cell invasion, and metastasis [24-26, 41, 48, 49, 64-68] . Although the physiological functions of syndecan-1 in the chorionic villi of the placenta are still obscure, we propose that syndecan-1 may play an important role during pregnancy based on its high expression in this fetal tissue and its unique localization to the maternal-fetal barrier where the fetus comes into direct contact with maternal blood and the immune system.
Since syndecan-1 has anti-inflammatory roles by binding to and removing chemokines from cell surfaces after shedding [24, 26, 41, 65, 67] , it is possible that the decreased shedding/secretion of syndecan-1 from the syncytiotrophoblast in preeclampsia and HELLP syndrome may promote the exaggeration of the maternal systemic inflammation found in these syndromes. Syndecan-1 also has a central role in angiogenesis as it can bind to many growth factors (e.g., fibroblast growth factor 2, hepatocyte growth factor, transforming growth factor beta, and vascular endothelial growth factor), activate them, and promote angiogenesis [24, 26, 65] . Therefore, it is possible that there may be a link between decreased maternal serum syndecan-1 concentrations and the anti-angiogenic state in preeclampsia [16, 18, 20, 21] . Considering the important role of this proteoglycan in cell signaling [24, 25, 65] , the changes in syncytiotrophoblastic syndecan-1 transport and localization may lead to altered signaling and pro-inflammatory changes in the trophoblast, which have been observed in preeclampsia [13, 23] .
Conclusions
Syncytiotrophoblastic syndecan-1 expression is dependent on trophoblast differentiation, and trophoblastic syndecan-1 release is decreased in preeclampsia and HELLP syndrome. This phenomenon may be related to the disturbed cortical actin cytoskeleton in the syncytiotrophoblast and associated with maternal anti-angiogenic and pro-inflammatory states in these syndromes.
